How to use the NGENLA▼ (somatrogon) pen

To go directly to the section of video that interests you, use the dots in the playbar beneath (these may only be visible in landscape/full screen).

This non-promotional video intended for UK patients or carers of UK patients prescribed NGENLA has been developed and funded by Pfizer. This video does not replace the package leaflet. Please consult the package leaflet or consult your healthcare team if you have any questions.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard or search MHRA Yellow Card in the Google Play or Apple App Store for how to report side effects.

This website is intended for patients prescribed NGENLA in the UK to provide information on this medicine, and its uses. It is not intended to replace in any way the advice of a healthcare professional. For specific information about your condition and/or its detection, diagnosis, prognosis, administration and, where applicable, appropriate treatment for each specific case, please promptly consult a doctor or other qualified healthcare professional.

This website is brought to you by Pfizer Limited, a company registered in England and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent CT13 9NJ, VAT registration number GB201048427